drug
(albuterol sulfate + budesonide)
Marketedupdated 3mo agoby AstraZeneca Pharmaceuticals LP
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- drugbudesonide DR1 co-mentions · 1 sources
- drugbudesonide ER1 co-mentions · 1 sources
- drugBUDESONIDE1 co-mentions · 1 sources
- drugPulmicort Turbohaler1 co-mentions · 1 sources
- companyAstraZeneca Pharmaceuticals LP1 co-mentions · 1 sources
- tagRecall1 co-mentions · 1 sources
- drugPulmicort1 co-mentions · 1 sources
indications
investigational
Asthma
all catalysts(0)
nothing on the calendar yet
Trials studying (albuterol sulfate + budesonide)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 15, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- May 28, 2030method-of-use (U-3509)US 94150093.8y
FDA exclusivities (2)
- Sep 15, 2028M-317Method (3y)2.1y
- Jan 10, 2026NPNP
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that